Iron Chelators in Neurodegenerative Disease
Overview
flowchart TD
Iron["Iron"] -->|"causes"| Phospholipid_Peroxidation["Phospholipid Peroxidation"]
Iron["Iron"] -->|"involved in"| Neurotransmitter_Synthesis["Neurotransmitter Synthesis"]
Iron["Iron"] -->|"involved in"| Mitochondrial_Metabolism["Mitochondrial Metabolism"]
iron["iron"] -->|"drives"| ferroptosis["ferroptosis"]
iron["iron"] -->|"binds"| FTH1["FTH1"]
Iron["Iron"] -->|"causes"| Ferroptosis["Ferroptosis"]
Iron["Iron"] -->|"mediates"| Ferroptosis["Ferroptosis"]
Iron["Iron"] -->|"involved in"| Ferroptosis["Ferroptosis"]
Iron["Iron"] -->|"involved in"| Myelination["Myelination"]
Iron["Iron"] -->|"causes"| Oxidative_Stress["Oxidative Stress"]
iron["iron"] -->|"mediates"| oxidative_stress["oxidative stress"]
iron["iron"] -->|"binds"| FTMT["FTMT"]
Iron["Iron"] -->|"associated with"| Microglia["Microglia"]
Iron["Iron"] -->|"associated with"| Ferroptosis["Ferroptosis"]
style IRON fill:#4fc3f7,stroke:#333,color:#000
<table class="infobox infobox-therapeutic"> <tr> <th class="infobox-header" colspan="2">Iron Chelators in Neurodegenerative Disease</th> </tr> <tr> <td class="label">Name</td> <td><strong>Iron Chelators in Neurodegenerative Disease</strong></td> </tr> <tr> <td class="label">Type</td> <td>Therapeutic</td> </tr> </table>
...
Iron Chelators in Neurodegenerative Disease
Overview
Mermaid diagram (expand to render)
<table class="infobox infobox-therapeutic"> <tr> <th class="infobox-header" colspan="2">Iron Chelators in Neurodegenerative Disease</th> </tr> <tr> <td class="label">Name</td> <td><strong>Iron Chelators in Neurodegenerative Disease</strong></td> </tr> <tr> <td class="label">Type</td> <td>Therapeutic</td> </tr> </table>
Iron chelation therapy represents a promising neuroprotective strategy for neurodegenerative diseases characterized by iron accumulation in the brain["@crapper1991"]. Iron dysregulation and oxidative stress are common pathological features in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders["@ward2014"]. Iron chelators work by removing excess redox-active iron that would otherwise catalyze the production of toxic [reactive oxygen species](/entities/reactive-oxygen-species) (ROS), thereby potentially slowing disease progression.
Iron Homeostasis in the Brain
The brain requires iron for essential functions:
Myelin production : Iron is a cofactor for oligodendrocyte myelination
Neurotransmitter synthesis : Tyrosine hydroxylase and dopamine synthesis require iron
Mitochondrial function : Iron-sulfur cluster biosynthesis
DNA synthesis : Ribonucleotide reductase requires iron
Iron Dysregulation in Neurodegeneration Multiple mechanisms contribute to iron accumulation in neurodegenerative diseases:
Impaired iron export : Dysfunction of ferroportin (SLC40A1) and ceruloplasmin
Increased iron uptake : Upregulation of transferrin receptor and DMT1
Microglial iron release : Chronic neuroinflammation leads to iron accumulation
[Blood-brain barrier](/entities/blood-brain-barrier) disruption : Permeability allows serum iron entry
Alzheimer's Disease
Iron Accumulation Patterns Iron accumulates in:
[Hippocampus](/brain-regions/hippocampus) : Particularly in the CA1 region and subiculum
Amyloid plaques : Co-localization with Aβ deposits
Neurofibrillary tangles : Associated with hyperphosphorylated [tau](/proteins/tau)
Basal forebrain cholinergic [neurons](/entities/neurons) : Vulnerability to iron toxicity
Iron's Role in AD Pathogenesis Redox-active iron contributes to AD through multiple mechanisms[@rottkamp2001]:
[Amyloid-beta](/proteins/amyloid-beta) aggregation : Iron promotes Aβ oligomerization
Tau hyperphosphorylation : Iron activates kinases including [GSK-3β](/entities/gsk3-beta)
Lipid peroxidation : Iron catalyzes ROS formation in membranes
Synaptic dysfunction : Iron-induced oxidative stress impairs neurotransmission
Chelation Therapy in AD Clinical trials have evaluated iron chelators in AD:
Deferoxamine (Desferal) : Early trials showed slowed cognitive decline[@crapper1993]
Clioquinol : Phase 2 trial demonstrated reduced cognitive decline[@ritchie2003]
Deferasirox : Currently under investigation[@lovell2018]
Parkinson's Disease
Iron Accumulation Patterns PD shows striking iron deposition:
Substantia nigra pars compacta : Marked iron increase in dopaminergic neurons
Globus pallidus : Iron accumulation in output nuclei
Red nucleus : Iron deposits in motor-related structures
Iron's Role in PD Pathogenesis Iron contributes to dopaminergic neuron death[@weinreb2007]:
Mitochondrial dysfunction : Iron catalyzes Fenton reactions
[Alpha-synuclein](/proteins/alpha-synuclein) aggregation : Iron promotes α-syn fibrillization
Neuromelanin degradation : Releases stored iron
Microglial activation : Iron amplifies neuroinflammation
Chelation Therapy in PD Promising therapeutic approaches include:
Deferoxamine : Neuroprotective in MPTP models[@benshlomo2007]
Deferasirox : Phase 2 trial in PD patients showed reduced motor progression[@devos2014]
Novel chelators : GPX-456 and others in development[@kaur2019]
Amyotrophic Lateral Sclerosis
Iron Dysregulation in ALS ALS shows iron accumulation in:
Motor [cortex](/brain-regions/cortex) : Iron deposits in upper motor neurons
Spinal cord : Motor neuron loss associated with iron
Muscle : Elevated systemic iron markers
Iron's Role in ALS Iron contributes to motor neuron injury[@orellana2016]:
Oxidative stress : Increased ROS production
Mitochondrial dysfunction : Impaired energy metabolism
Excitotoxicity : Iron-glutamate interactions
Protein aggregation : Enhanced misfolding
Iron Chelators in Clinical Use
Deferoxamine (Desferal)
Administration : Subcutaneous infusion (preferred for brain delivery)
Blood-brain barrier penetration : Limited, but clinical benefit observed
Side effects : Ototoxicity, visual disturbances, injection site reactions
Dosing : 20-40 mg/kg/day subcutaneously
Deferasirox (Exjade, Jadenu)
Administration : Oral daily
BBB penetration : Moderate
Side effects : Gastrointestinal symptoms, rash, renal/hepatic function changes
Advantages : Better compliance than deferoxamine
Clioquinol
Mechanism : Metal-protein attenuating compound (MPAC)
BBB penetration : Good
Advantages : Modulates Aβ and α-syn aggregation
Status : Phase 2/3 trials in AD and PD[@chen2020]
Novel Chelators in Development
M30
Novel iron chelator with neuroprotective properties
Activates Nrf2 pathway
Modulates [autophagy](/entities/autophagy)
Promising for AD and PD[@kalfon2017]
VK28
Brain-penetrant iron chelator
Antioxidant and anti-inflammatory effects
Under investigation for PD[@zhang2019]
Glycine-Proline-Lysine (GPK)
Tripeptide chelator
Low systemic toxicity
Currently in preclinical testing
Combination Approaches
Chelation Plus Antioxidants
Alpha-lipoic acid : Synergistic oxidative stress reduction
Coenzyme Q10 : Mitochondrial protection
Vitamin E : Lipid peroxidation prevention
Chelation Plus Anti-amyloid Therapy
Combined Aβ/α-syn targeting with metal modulation
Enhanced protein clearance
Potential disease-modifying effects
Allen Brain Atlas Resources
[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
See Also
Iron Metabolism in the Brain
[Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress)
[Alzheimer's Disease Treatments](/diseases/alzheimers-disease)
[Parkinson's Disease Treatments](/diseases/parkinsons-disease)
[Neuroinflammation in Neurodegeneration](/diseases/neurodegeneration)
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
[ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: ACSL4
[Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy](/hypothesis/h-ac55ff26) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: ALOX15
[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
Related Analyses:
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v4-20260402065846) 🔄
[Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v3-20260402063622) 🔄
[Extracellular vesicle biomarkers for early AD detection](/analysis/SDA-2026-04-02-gap-ev-ad-biomarkers) 🔄
Show full description